BBPvsCANCETF Comparison
VS
Virtus LifeSci Biotech Products ETF (BBP) and Tema Oncology ETF (CANC) belong to the same industry segment: Tomorrow's Treatments. Both ETFs have the same top 3 sector exposures: and Healthcare. BBP is less expensive with a Total Expense Ratio (TER) of 0.34%, versus 0.99% for CANC. BBP is up 21.54% year-to-date (YTD) with +$40M in YTD flows. CANC performs worse with 18.41% YTD performance, and +$52M in YTD flows. Run a side-by-side ETF comparison of BBP and CANC below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
BBP vs CANC performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/27/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | BBP CANC | +0.94%-0.28% | +15.67%+8.61% | +21.54%+18.41% | +56.59%+53.77% | +81.31%n/a | +94.15%n/a |
| Flows | BBP CANC | +$10M-$2M | +$28M+$3M | +$40M+$52M | +$52M+$76M | +$55M- | +$48M- |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | BBP CANC | +26.32%+23.01% | +24.02%+22.71% | +24.33%n/a | +26.47%n/a |
| Max drawdown | BBP CANC | -7.49%-5.93% | -9.59%-9.20% | -25.54%n/a | -37.61%n/a |
| Max drawdown duration | BBP CANC | 44d47d | 48d67d | 292dn/a | 586dn/a |
Trading data
BBP | CANC | |
Last sale 7/28/2026 at 1:30 PM | $97.69 | $41.18 |
| Previous close 07/27/2026 | $97.26 | $41.10 |
| Consolidated volume 07/27/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of June 30, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
CANC
is actively managed and doesn’t replicate an indexBBP | CANC | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 7/28/2026 at 1:30 PM
Live
Closed
BBP | CANC | |
|---|---|---|
| Last price | $97.69 | $41.18 |
| 1D performance | +0.45% | +0.20% |
| AuM | $96.94 M | $195.62 M |
| E/R | 0.34% | 0.99% |
Characteristics
BBP | CANC | |
|---|---|---|
| Management strategy | Passive | Active |
| Provider | VIRTUS Investment Partners | Tema |
| Benchmark | LifeSci Biotechnology Products Index | - |
| N° of holdings | 66 | 56 |
| Asset class | Equities | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 16, 2014 | August 15, 2023 |
| ESG | No | No |
Advertisement
Exposure
Countries
BBP
USA
89.11%
Other
10.89%
CANC
USA
80.59%
Switzerland
9.85%
Other
9.56%
Sectors
BBP
Healthcare
89.47%
Other
10.53%
CANC
Healthcare
99.28%
Other
0.72%
Advertisement
Diversification
BBP
Total weight of top 15 holdings out of 15
87.15%
CANC
Total weight of top 15 holdings out of 15
55.76%
Top 15 holdings
Data as of June 30, 2026
BBP
Verastem, Inc.
44.58%
Legend Biotech Corp.
41.98%
Agios Pharmaceuticals, Inc.
0.05%
BioCryst Pharmaceuticals, Inc.
0.05%
BioMarin Pharmaceutical, Inc.
0.05%
Rigel Pharmaceuticals, Inc.
0.05%
Crinetics Pharmaceuticals, Inc.
0.05%
Madrigal Pharmaceuticals, Inc.
0.05%
BioNTech SE
0.05%
Iovance Biotherapeutics, Inc.
0.05%
Rhythm Pharmaceuticals, Inc.
0.05%
Alnylam Pharmaceuticals, Inc.
0.05%
Incyte Corp.
0.05%
Sarepta Therapeutics, Inc.
0.05%
Omeros Corp.
0.05%
CANC
Revolution Medicines, Inc.
6.32%
Eli Lilly & Co.
5.24%
Cogent Biosciences, Inc.
4.94%
Novartis AG
4.19%
Roche Holding AG
3.93%
Legend Biotech Corp.
3.70%
Merck & Co., Inc.
3.66%
Bristol Myers Squibb Co.
3.33%
AstraZeneca PLC
3.15%
Johnson & Johnson
3.09%
AbbVie, Inc.
3.08%
Immunome, Inc.
2.87%
Exelixis, Inc.
2.85%
Nuvalent, Inc.
2.73%
IDEAYA Biosciences, Inc.
2.68%
Frequently asked questions about BBP and CANC
How have the BBP and CANC ETFs performed in 2026?
As of July 27, 2026, BBP is up 21.54% year-to-date (YTD), while CANC has returned 18.41%. That puts BBP better performer ahead so far this year.
Which ETF is attracting more investor money: BBP or CANC?
Year-to-date, the BBP ETF saw +$40M in flows, compared to +$52M for CANC.
Which ETF is more volatile: BBP or CANC?
Over the past year, BBP had a volatility of 24.02%, while CANC experienced 22.71%.
Which ETF is bigger: BBP or CANC?
As of July 27, 2026, BBP holds $96.94 M in assets under management (AUM), while CANC manages $195.62 M.
What sectors do the BBP and CANC ETFs invest in?
BBP leans toward sectors like Healthcare. Meanwhile, CANC focuses on Healthcare.
What are the top holdings of the BBP ETF and CANC ETF?
BBP top holdings include Verastem, Inc., Legend Biotech Corp. and Agios Pharmaceuticals, Inc.. CANC holds in its top three: Revolution Medicines, Inc., Eli Lilly & Co. and Cogent Biosciences, Inc..
Which ETF is more diversified: BBP or CANC?
BBP holds 66 securities with 87.15% of its assets in the top 15. CANC has 56 securities and a top 15 weight of 55.76%.
Advertisement
Advertisement
